濮阳东方医院看阳痿技术安全放心(濮阳东方医院妇科网络咨询) (今日更新中)

The Department of Defense announced on Friday the formation of the Unidentified Aerial Phenomena Task Force, which will be tasked with looking into reports of UFOs.The Pentagon says that task force’s mission is to detect, analyze and catalog unidentified aerial phenomena, better known as UFOs, that could potentially pose a threat to U.S. national security.“As DOD has stated previously, the safety of our personnel and the security of our operations are of paramount concern,” the Department of Defense said. “The Department of Defense and the military departments take any incursions by unauthorized aircraft into our training ranges or designated airspace very seriously and examine each report. This includes examinations of incursions that are initially reported as UAP when the observer cannot immediately identify what he or she is observing.”Sen. Marco Rubio confirmed the formation of the task force last month in an interview with Miami’s WFOR-TV."We have things flying over our military bases and places where we are conducting military exercises, and we don't know what it is and it isn't ours, so that's a legitimate question to ask,"Rubio said.In April, the Pentagon released videos of “unidentified aerial phenomena” captured by Navy pilots. One of the videos was from 2004, while another two were from 2015.“After a thorough review, the department has determined that the authorized release of these unclassified videos does not reveal any sensitive capabilities or systems, and does not impinge on any subsequent investigations of military air space incursions by unidentified aerial phenomena,” the Pentagon said in April. “DOD is releasing the videos in order to clear up any misconceptions by the public on whether or not the footage that has been circulating was real, or whether or not there is more to the videos.” 1846

The Department of Homeland Security is on heightened alert, watching for any election security issues.In the last week of October, hackers targeted at least six states, attempting to get into their voter databases and election security systems, according to the Boston Globe. Some states reported they had to block more than 50,000 log-in attempts that came from foreign countries.“The worst-case scenario is somehow a system is slowed down or brought down, or perhaps there’s some problems on election day, where voters have to wait longer,” says John Fortier, with the Bipartisan Policy Center. “But there are backup procedures and there are ways of recovering from this.”On Tuesday, the Department of Homeland Security reassured voters that their ballots are safe.“We have no indication of compromise of our nation’s election infrastructure that would prevent voting, change vote counts, or disrupt the ability to tally votes,” said their statement in part.“At this stage in the election, we’re not expecting it, certainly not to effect votes, and secondly there are lots of procedures to recover from this,” Fortier explains. “If there is a problem, there is a backup, both for voters and election administrators.”For now, the bigger concern has become misinformation online, including attempts to cause chaos and manipulate public opinion.Read the joint statement released by the Department of Homeland Security and Department of Justice in its entirety below:“Our agencies have been working in unprecedented ways to combat influence efforts and to support state and local officials in securing our elections, including efforts to harden election infrastructure against interference. Our goal is clear: ensure every vote is counted and counted correctly. At this time we have no indication of compromise of our nation’s election infrastructure that would prevent voting, change vote counts, or disrupt the ability to tally votes.”“But Americans should be aware that foreign actors – and Russia in particular – continue to try to influence public sentiment and voter perceptions through actions intended to sow discord. They can do this by spreading false information about political processes and candidates, lying about their own interference activities, disseminating propaganda on social media, and through other tactics. The American public can mitigate these efforts by remaining informed, reporting suspicious activity, and being vigilant consumers of information, as discussed below.”“The United States will not tolerate foreign interference in our elections from Russia, China, Iran, or other nations. As noted in a  joint statement on October 19, 2018, such actions are a threat to our democracy, and identifying and preventing this interference is one of our highest priorities. On September 12, President Trump signed an executive order that makes clear the U.S. government will not hesitate to defend our electoral processes or punish those who attempt to undermine them.” “Our agencies have been making preparations for nearly two years in advance of these elections and are closely engaged with officials on the ground to help them ensure the voting process is secure. Americans can rest assured that we will continue to stay focused on this mission long after polls have closed.” 3337

The FBI has taken custody of multiple suspicious packages sent to military locations in the Washington, DC area, a law enforcement official said Monday. The official said two of the packages were sent to Fort Belvoir and Fort McNair.At least one package, sent to the National Defense University at Fort McNair in Washington, DC, contained explosive material and was ultimately rendered safe. That package arrived at 8:30 a.m. ET and the building was evacuated immediately, according to Army spokesman Michael L. Howard."At 12:10 p.m., 52nd Army Explosive Ordnance Disposal from Fort Belvoir, VA, confirmed the package tested positive for black powder and residue," Howard said in a statement. "The X-ray conducted indicates suspected GPS and an expedient fuse were attached. The package was rendered safe. No injuries are reported."Scanning machines at the facilities detected the suspicious materials upon receipt and the packages are being examined at the FBI lab in Quantico, Virginia, the law enforcement official said.The National Defense University at Fort McNair was cleared for re-entry after K-9 sweep and personnel returned to the building by 1:15 pm ET.Another Army spokesman confirmed a suspicious package incident at Fort Belvoir and said that package has been rendered safe. 1296

The CBS board of directors is in the process of picking outside counsel to conduct an investigation after company CEO Les Moonves was accused of sexual misconduct.In a statement, CBS said that "no other action" was taken on the matter at Monday's board meeting.The meeting was scheduled before a bombshell report in The New Yorker Friday detailed allegations against the CEO. Six women told the magazine that Moonves sexually harassed them.In a statement to The New Yorker that was also obtained by CNNMoney on Friday, Moonves said he has "promoted a culture of respect and opportunity for all employees" throughout his tenure at CBS."I recognize that there were times decades ago when I may have made some women uncomfortable by making advances," Moonves said. "Those were mistakes, and I regret them immensely. But I always understood and respected — and abided by the principle — that 'no' means 'no,' and I have never misused my position to harm or hinder anyone's career."The idea that Moonves should step aside during the probe was raised by at least some board members this weekend, according to one source who spoke to CNNMoney on Sunday.The board also said on Monday that it would postpone its annual meeting of stockholders, which was scheduled to be held August 10. A new date has not yet been announced. It was not clear why the board decided to reschedule that meeting. 1400

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

来源：资阳报